Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus

Circulation. 2014 Jun 24;129(25):2705-13. doi: 10.1161/CIRCULATIONAHA.113.008221.

Authors

Venu Menon¹, A Michael Lincoff²

Affiliations

¹ From the Robert & Suzanne Tomsich Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.
² From the Robert & Suzanne Tomsich Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH. [email protected].

PMID: 24958753
DOI: 10.1161/CIRCULATIONAHA.113.008221

No abstract available

Keywords: United States Office of National Drug Control Policy; coronary disease; diabetes mellitus.

MeSH terms

Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic / trends
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Drug Evaluation / trends*
Endpoint Determination
Humans
Hypoglycemic Agents / therapeutic use*
Prevalence
Program Development*
Risk Factors

Substances

Hypoglycemic Agents